UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Bone metastatic burden as a predictor of survival benefit from prostate radiotherapy in newly-diagnosed metastatic prostate cancer

Ali, A; Hoyle, AP; Parker, CC; Brawley, CD; Cook, A; Amos, C; Calvert, J; ... STAMPEDE investigators; + view all (2021) Bone metastatic burden as a predictor of survival benefit from prostate radiotherapy in newly-diagnosed metastatic prostate cancer. JAMA oncology , 7 (4) pp. 555-563. 10.1001/jamaoncol.2020.7857. Green open access

[thumbnail of Brawley_jamaoncology_ali_2021_oi_200113_1617385021.78094.pdf]
Preview
Text
Brawley_jamaoncology_ali_2021_oi_200113_1617385021.78094.pdf - Published Version

Download (583kB) | Preview

Abstract

Importance: Prostate radiotherapy (RT) improves survival in men with low-burden metastatic prostate cancer. However, owing to the dichotomized nature of metastatic burden criteria, it is not clear how this benefit varies with bone metastasis counts and metastatic site. Objective: To evaluate the association of bone metastasis count and location with survival benefit from prostate RT. Design, Setting, and Participants: This exploratory analysis of treatment outcomes based on metastatic site and extent as determined by conventional imaging (computed tomography/magnetic resonance imaging and bone scan) evaluated patients with newly diagnosed metastatic prostate cancer randomized within the STAMPEDE trial’s metastasis M1 RT comparison. The association of baseline bone metastasis counts with overall survival (OS) and failure-free survival (FFS) was assessed using a multivariable fractional polynomial interaction procedure. Further analysis was conducted in subgroups. Interventions: Patients were randomized to receive either standard of care (androgen deprivation therapy with or without docetaxel) or standard of care and prostate RT. Main Outcomes and Measures : The primary outcomes were OS and FFS. Results : A total of 1939 of 2061 men were included (median [interquartile range] age, 68 [63-73] years); 1732 (89%) had bone metastases. Bone metastasis counts were associated with OS and FFS benefit from prostate RT. Survival benefit decreased continuously as the number of bone metastases increased, with benefit most pronounced up to 3 bone metastases. A plot of estimated treatment effect indicated that the upper 95% CI crossed the line of equivalence (hazard ratio [HR], 1) above 3 bone metastases without a detectable change point. Further analysis based on subgroups showed that the magnitude of benefit from the addition of prostate RT was greater in patients with low metastatic burden with only nonregional lymph nodes (M1a) or 3 or fewer bone metastases without visceral metastasis (HR for OS, 0.62; 95% CI, 0.46-0.83; HR for FFS, 0.57; 95% CI, 0.47-0.70) than among patients with 4 or more bone metastases or any visceral/other metastasis (HR for OS, 1.08; 95% CI, 0.91-1.28; interaction P = .003; HR for FFS, 0.87; 95% CI, 0.76-0.99; interaction P = .002). Conclusions and Relevance: In this exploratory analysis of a randomized clinical trial, bone metastasis count and metastasis location based on conventional imaging were associated with OS and FFS benefit from prostate RT in M1 disease.

Type: Article
Title: Bone metastatic burden as a predictor of survival benefit from prostate radiotherapy in newly-diagnosed metastatic prostate cancer
Open access status: An open access version is available from UCL Discovery
DOI: 10.1001/jamaoncol.2020.7857
Publisher version: https://doi.org/10.1001/jamaoncol.2020.7857
Language: English
Additional information: This is an open access article distributed under the terms of the CC-BY License. © 2021 Ali A et al. JAMA Oncology.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL
URI: https://discovery.ucl.ac.uk/id/eprint/10116493
Downloads since deposit
28Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item